Wednesday, 9 August 2017

Global Crohns Disease (CD) Market By Manufacturers, Type And Application, Regions, Forecast to 2019

Crohns Disease (CD) Market 2017

About CD CD is an ongoing condition that causes inflammation of the digestive tract or the GI tract. CD may also be named as ileitis, granulomatous enteritis or colitis, regional enteritis, or terminal ileitis. The exact etiology of CD is unknown. Usually, CD affects the small intestine and the beginning of the large intestine. However, the disease can disturb any part of the GI tract, from the mouth to the anus. CD can occur at any age; however, it is usually first diagnosed in people in their teens and twenties.

TechNavio's analysts forecast the Global CD market to grow at a CAGR of 2.84 percent over the period 2014-2019. 

Covered in this Report
This report covers the present scenario and the growth prospects of the Global CD market for the period 2015–2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CD. The Global CD market can be divided into five segments: 5-ASA, Antibiotics, Biologicals, Corticosteroids, and Immunomodulators.

        
TechNavio's report, the Global CD Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global CD market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions • Americas
• APAC
• EMEA

Key Vendors • AbbVie
• Astra Zeneca
• Biogen Idec
• Johnson & Johnson
• Takeda Pharmaceutical
• UCB

Other Prominent Vendors • Amgen
• Boehringer Ingelheim
• Celltrion
• ChemoCentryx
• Ferring Pharmaceuticals
• Merck
• Mitsubishi Tanabe
• Novartis
• Novo Nordisk
• Pfizer

Market Driver • Increase in CD Prevalence
• For a full, detailed list, view our report

Market Challenge • Multiple Patent Expiry
• For a full, detailed list, view our report

Market Trend • Increase in Strategic Collaborations
• For a full, detailed list, view our report

Key Questions Answered in this Report • What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Complete Report Details @ https://www.wiseguyreports.com/reports/38599-global-crohns-disease-cd-market-2015-2019                                                                                                                                                                                                                               
Table of Contents         
  1. Executive Summary
    02. List of Abbreviations
    03. Scope of the Report
        03.1 Market Overview
        03.2 Product Offerings
          03.2.1 Product Profiles
    04. Market Research Methodology
        04.1 Market Research Process
        04.2 Research Methodology
    05. Introduction
    06. Disease Overview
        06.1 Understanding the Disease
        06.2 Etiology
          06.2.1 Autoimmune Reaction
          06.2.2 Genes
          06.2.3 Environment
        06.3 Stages of CD
        06.4 Epidemiology
          06.4.1 Global
          06.4.2 US
          06.4.3 UK
        06.5 Symptoms
          06.5.1 Diarrhea
          06.5.2 Fever & Fatigue
          06.5.3 Abdominal Pain & Cramping
          06.5.4 Perianal Disease & Blood in the Stool
          06.5.5 Reduced Appetite & Weight Loss
        06.6 Diagnosis & Testing
          06.6.1 Early Tests and Exams
          06.6.2 Endoscopy and Biopsy
          06.6.3 Chromoendoscopy
          06.6.4 Small Intestinal Imaging
        06.7 Treatment
          06.7.1 Medication
          06.7.2 Diet & Nutrition
          06.7.3 Surgery
    07. CD Pipeline Landscape
        07.1 Some of the emerging therapeutic options for CD:
    08. Market Landscape
        08.1 Market Overview
        08.2 Market Size and Forecast
        08.3 CD Market in the US
          08.3.1 Market Size and Forecast
        08.4 CD Market in Japan
          08.4.1 Market Size and Forecast
    09. Market Segmentation by Drug Class
        09.1 Five Forces Analysis
    10. Geographical Segmentation
    11. Buying Criteria
    12. Market Growth Drivers
    13. Drivers and their Impact
    14. Market Challenges
    15. Impact of Drivers and Challenges
    16. Market Trends
    17. Trends and their Impact
    18. Vendor Landscape
        18.1 Competitive Scenario
          18.1.1 Key News
          18.1.2 Mergers and Acquisitions
        18.2 Market Share Analysis 2014
          18.2.1 AbbVie
          18.2.2 Astra Zeneca
          18.2.3 Biogen Idec
          18.2.4 Johnson and Johnson
          18.2.5 Takeda Pharmaceutical
          18.2.6 UCB
        18.3 Other Prominent Vendors
    19. Key Vendor Analysis
        19.1 AbbVie Inc.     19.1.1 Key Facts
          19.1.2 Business Overview
          19.1.3 Product Segmentation by Revenue 2013
          19.1.4 Product Segmentation by Revenue 2012 and 2013
          19.1.5 Sales by Geography
          19.1.6 Business Strategy
          19.1.7 Key Developments
          19.1.8 SWOT Analysis
    19.2 AstraZeneca plc       19.2.1 Key Facts
          19.2.2 Business Overview
          19.2.3 Business Segmentation by Revenue 2013
          19.2.4 Business Segmentation by Revenue 2011-2013
          19.2.5 Sales by Geography
          19.2.6 Business Strategy
          19.2.7 Key Developments
          19.2.8 SWOT Analysis
        19.3 Biogen Idec       19.3.1 Key Facts
          19.3.2 Business Overview
          19.3.3 Business Segmentation by Revenue 2013
          19.3.4 Geographical Segmentation by Revenue 2013
          19.3.5 Business Strategy
          19.3.6 Key Developments
          19.3.7 SWOT Analysis
        19.4 Johnson & Johnson       19.4.1 Key Facts
          19.4.2 Business Overview
          19.4.3 Business Segmentation by Revenue 2013
          19.4.4 Business Segmentation by Revenue 2012 and 2013
          19.4.5 Geographical Segmentation by Revenue 2013
          19.4.6 Business Strategy
          19.4.7 Recent Developments
          19.4.8 SWOT Analysis
        19.5 Takeda Pharmaceuticals       19.5.1 Key Facts
          19.5.2 Business Overview
          19.5.3 Business Segmentation by Revenue 2013
          19.5.4 Business Segmentation by Revenue 2013
          19.5.5 Geographical Segmentation by Revenue 2013
          19.5.6 Business Strategy
          19.5.7 Recent Developments
          19.5.8 SWOT Analysis
        19.6 UCB       19.6.1 Key Facts
          19.6.2 Business Overview
          19.6.3 Product Segmentation by Revenue 2013
          19.6.4 Product Segmentation by Revenue 2012 and 2013
          19.6.5 Geographical Segmentation by Revenue 2013
          19.6.6 Business Strategy
          19.6.7 Recent Developments
          19.6.8 SWOT Analysis
    20. Other Reports in this Series    
 Continued…….

For accessing accurate and deep understanding and to gain latest insights and key developments in the area of your interest, we also have a list of conferences in which you will be interested in, for more information, cordially check :


For updating knowledge or for thoroughly understanding various terminologies, we also have vast list of seminars for your reference, for more information cordially check :


CONTACT US:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
www.wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Posted by at
Labels: , , , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)